Investment
Features
FeesSafety
Academy
More
Pluang+

Chanson International announces 100-for-1 share consolidation effective May 7, 2026.

Company Fundamentals
05 May 2026
GlobeNewsWire
View Source
Neutral
pluang ai news

Chanson International Holding declared a 100-for-1 share consolidation effective May 7, 2026, reducing the number of outstanding shares and increasing the par value per share. This move will adjust the company's authorized and issued shares, consolidating every 100 shares into one without fractional shares issued. The consolidation aims to streamline the stock structure as Chanson operates bakery and beverage stores in China and the U.S. Shares will continue trading under the symbol CHSN on Nasdaq with a new CUSIP number. Investors should note the changes in share count and par value but expect no change in overall ownership percentage.

More News

Over 180 companies develop 200+ PD-1/PD-L1 inhibitors, reshaping cancer treatment landscape.

Over 180 companies develop 200+ PD-1/PD-L1 inhibitors, reshaping cancer treatment landscape.

A new report reveals more than 180 companies are actively developing over 200 PD-1 and PD-L1 inhibitors, a class of immunotherapies that boost the immune system to fight cancer. These drugs target various cancers including lung, bladder, liver, and e...

Market News
Bullish
25 minutes ago
Eversource named to TIME's America's Best Companies for 2026 for employee and sustainability excellence

Eversource named to TIME's America's Best Companies for 2026 for employee and sustainability excellence

Eversource has been recognized on TIME's list of America's Best Companies for 2026, highlighting its strong commitment to employee satisfaction, operational excellence, and sustainability. The ranking is based on surveys of over 217,000 employees and...

Market News
Bullish
25 minutes ago
Head and neck squamous cell carcinoma market to grow at 10.5% CAGR by 2036 driven by new immunotherapies

Head and neck squamous cell carcinoma market to grow at 10.5% CAGR by 2036 driven by new immunotherapies

The head and neck squamous cell carcinoma (HNSCC) market is projected to grow at a compound annual growth rate (CAGR) of 10.5% from 2026 to 2036, fueled by rising cancer incidence and the introduction of novel immunotherapies and targeted treatments....

Market News
Bullish
25 minutes ago
Poolside launches Laguna S 2.1, a powerful 118B-parameter AI model for coding, running on a single desktop.

Poolside launches Laguna S 2.1, a powerful 118B-parameter AI model for coding, running on a single desktop.

Poolside has released Laguna S 2.1, a 118-billion-parameter open-weight AI model designed for agentic coding that matches or outperforms much larger models. It is compact enough to run on a single NVIDIA DGX Spark desktop and is available under an op...

Others
Bullish
25 minutes ago
Law firm probes Omeros over stock drop after EMA rejects drug approval

Law firm probes Omeros over stock drop after EMA rejects drug approval

Pomerantz LLP is investigating Omeros Corporation for potential securities fraud following a significant stock price drop. The decline occurred after the European Medicines Agency's Committee for Medicinal Products for Human Use issued a negative opi...

Market News
Bearish
29 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App